C型慢性肝炎に対するペグインターフェロン, リバビリン併用療法24週時の血清HCV RNA陰性予測におけるコア抗原の有用性 Serum HCV core antigen level is a useful prediction marker of serum HCV RNA negative at 24-week-treatment with peginterferon and ribavirin in patients with chronic hepatitis C

この論文にアクセスする

この論文をさがす

著者

抄録

We analyzed prediction markers of serum HCV RNA negative at 24-week-treatment with peginterferon and ribavirin for patients with chronic hepatitis C in Japan. Serum level of a pre-treatment HCV core antigen was significantly lower in patients negative for HCV RNA than in patients positive for HCV RNA at 24-week-treatment (p<0.01). The patients with a pre-treatment HCV core antigen level lower than 15000fmol/L and HCV core antigen loss (<20fmol/L) after one-month-treatment showed significantly higher negativity in serum HCV RNA at 24-week-treatment (p<0.05 and p<0.02, respectively). These date strongly suggest that the pre-treatment HCV core antigen level as well as HCV core antigen loss after one-month-treatment are useful prediction markers in efficacy of the combination therapy with peginterferon and ribavirin.<br>

収録刊行物

  • 肝臓 = ACTA HEPATOLOGICA JAPONICA  

    肝臓 = ACTA HEPATOLOGICA JAPONICA 47(8), 411-412, 2006-08-25 

    The Japan Society of Hepatology

参考文献:  4件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018264617
  • NII書誌ID(NCID)
    AN00047770
  • 本文言語コード
    JPN
  • 資料種別
    SHO
  • ISSN
    04514203
  • データ提供元
    CJP書誌  J-STAGE 
ページトップへ